drug pricing

Politics By Nicholas Florko

Underpinning Sinema’s outspoken opposition to major drug pricing reforms: her close ties to Arizona biotechs

Pharmalot By Ed Silverman

FDA approves an interchangeable biosimilar version of Humira, but health care savings are dubious

Pharmalot By Ed Silverman

Pfizer will use a warranty to refund the cost of a lung cancer drug if it doesn’t work

First Opinion By Matt Salo

Much Adu(helm) about nothing: New Alzheimer’s drug threatens state Medicaid budgets

First Opinion By Dana P. Goldman and Tomas J. Philipson

Biosimilars competition helps patients more than generic competition

Pharmalot By Ed Silverman

Lilly cuts the wholesale price on some insulin products, but impact is likely to be limited

Pharmalot By Ed Silverman

Inflation and rebates caused wholesale prices on medicines to drop in second quarter

Politics By Rachel Cohrs and Nicholas Florko

In May, 10 moderate Democrats opposed major drug pricing reform. Ahead of a key vote, that list is shrinking

Pharmalot By Ed Silverman

WHO adds Regeneron drug to recommended Covid-19 treatments, but criticizes its pricing

First Opinion By John LaMattina

Even me-too drugs matter when it comes to new medicines

Pharmalot By Ed Silverman

Federal officials move closer to penalizing drug makers for failing to offer discounts to safety-net hospitals

D.C. Diagnosis By Nicholas Florko

Scott Gottlieb: Trump’s shadow FDA commissioner during Covid-19?

Health By Michelle Andrews — Kaiser Health News

Biosimilar drugs gain ground in U.S., but concerns linger about when patients can switch

Pharmalot By Ed Silverman

U.S. lawmakers accuse patent office of weakening challenges and allowing drug prices to rise

Exclusive By Rachel Cohrs

Senate proposes expanding pharma penalties for hiking drug prices

Politics By Nicholas Florko and Rachel Cohrs

‘A solid black eye’: Drug pricing reform advocates scramble to reset after setback in Congress

First Opinion By Joseph P. Allen

President Biden: Don’t misuse Bayh-Dole march-in rights

Pharmalot By Ed Silverman

A ‘wonky’ congressional report will be a pharma talking point in the drug pricing debate

Politics By Rachel Cohrs

Moderate Democrats sink Pelosi’s aggressive drug pricing bill in key committee vote

Pharmalot By Ed Silverman

Safety-net hospitals take big markups on cancer drugs for commercially insured patients, study finds

First Opinion By Peter Kolchinsky and Daphne Zohar

Congress is about to legislate a future without new medicines. We have a better plan

Politics By Rachel Cohrs

Virtual Event: The 340B drug discount program is at a crossroads. What’s next?

Politics By Nicholas Florko and Rachel Cohrs

Key senator opposes Democrats’ target for drug pricing savings

Politics By Rachel Cohrs

House moderates rebel against Pelosi drug pricing plan, leaving bill’s fate uncertain

First Opinion By Alfred Engelberg

Outdated rule increases Medicare’s costs for generic drugs by $26 billion a year